Cardiovascular disease and cancer are the two leading causes of morbidity and mortality in
the world. The emerging field of cardio-oncology has revealed that these seemingly …

A novel, common, and potent cardiovascular risk factor has recently emerged: clonal
hematopoiesis of indeterminate potential (CHIP). CHIP arises from somatic mutations in …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

The considerable progress made in the field of cancer treatment has led to a dramatic
improvement in the prognosis of patients with cancer. However, toxicities resulting from …

Background Patients with cancer and cancer survivors are at increased risk for incident
heart failure, but there are conflicting data on the long-term risk for other cardiovascular …

The development of a wide range of novel antineoplastic therapies has improved the
prognosis for patients with a wide range of malignancies, which has increased the number …

Advances in cancer treatments have improved clinical outcomes, leading to an increasing
population of cancer survivors. However, this success is associated with high rates of short …

Minority and underresourced communities experience disproportionately high rates of fatal
cancer and cardiovascular disease. The intersection of these disparities within the …

The population of patients with cancer is rapidly expanding, and the diagnosis and
monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in …